Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (2024)
- Authors:
- Scheinberg, Phillip
- Clé, Diego Villa
- Kim, Jin Seok
- Nur, Erfan
- Yenerel, Mustafa N.
- Barcellini, Wilma
- Bonito, Debora
- Giai, Valentina
- Hus, Marek
- Lee, YooJin
- Lekue, Cristina Barrenetxea
- Panse, Jens
- Ueda, Yasutaka
- Buatois, Simon
- Gentile, Brittany
- Kiialainen, Anna
- Patel, Himika
- Sreckovic, Sasha
- Uguen, Marianne
- Edwards, John
- Nagy, Zsolt
- Kulasekararaj, Austin G.
- Autor USP: CLÉ, DIEGO VILLA - FMRP
- Unidade: FMRP
- DOI: 10.1002/ajh.27413
- Subjects: ANTICORPOS MONOCLONAIS; DOENÇAS HEMATOLÓGICAS; MUTAÇÃO GENÉTICA; FARMACOTERAPIA; RESULTADO DE TRATAMENTO
- Language: Inglês
- Imprenta:
- Source:
- Título: American Journal of Hematology
- ISSN: 0361-8609
- Volume/Número/Paginação/Ano: v. 99, n. 9, p. 1757-1767, 2024
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SCHEINBERG, Phillip et al. Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, v. 99, n. 9, p. 1757-1767, 2024Tradução . . Disponível em: https://doi.org/10.1002/ajh.27413. Acesso em: 11 fev. 2026. -
APA
Scheinberg, P., Clé, D. V., Kim, J. S., Nur, E., Yenerel, M. N., Barcellini, W., et al. (2024). Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 99( 9), 1757-1767. doi:10.1002/ajh.27413 -
NLM
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee YJ, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria [Internet]. American Journal of Hematology. 2024 ; 99( 9): 1757-1767.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1002/ajh.27413 -
Vancouver
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee YJ, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria [Internet]. American Journal of Hematology. 2024 ; 99( 9): 1757-1767.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1002/ajh.27413 - Células mesenquimais estromais multipotentes da medula óssea no tratamento da anemia aplástica refratária ou em recaída
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells.: III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
- Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study
- Clonal hematopoiesis in telomere biology disorders associates with the underlying germline defect and somatic mutations in POT1, PPM1D, and TERT promoter
- Genomic-based machine learning towards prediction of the etiology of bone marrow failure syndromes
- Differential diagnosis of bone marrow failure syndromes guided by machine learning
- Pathogenic TERT promoter variants in telomere diseases
- Short telomere length in peripheral blood leukocytes in head and neck cancer: findings in a Brazilian cohort
- Molecular surveillance of the on-going SARS-COV-2 epidemic in Ribeirão Preto City, Brazil
Informações sobre o DOI: 10.1002/ajh.27413 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
